Efficacy of a Ceftazidime-Avibactam Combination in a Murine Model of Septicemia Caused by Enterobacteriaceae Species Producing AmpC or Extended-Spectrum β-Lactamases

Activities of Ceftazidime and Avibactam against β-Lactamase-Producing Enterobacteriaceae in a Hollow-Fiber Pharmacodynamic Model

(2014) Ken Coleman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

(2013) Christopher Lucasti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β -lactamase in Enterobacter cloacae

(2013) Christine Miossec et al.   Infection and Drug Resistance

ComparativeIn VitroandIn VivoEfficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa

(2012) Jared L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

(2012) José A. Vazquez et al.   CURRENT MEDICAL RESEARCH AND OPINION

Improving known classes of antibiotics: an optimistic approach for the future

(2012) Karen Bush   CURRENT OPINION IN PHARMACOLOGY

Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole

(2012) L.J. Dubreuil et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Avibactam is a covalent, reversible, non- -lactam  -lactamase inhibitor

(2012) D. E. Ehmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In VitroActivity of Ceftazidime-NXL104 against 396 Strains of β-Lactamase-Producing Anaerobes

(2011) Diane M. Citron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases

(2011) P. R. S. Lagacé-Wiens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors

(2011) Ken Coleman   CURRENT OPINION IN MICROBIOLOGY

In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae

(2011) Z. Aktaş et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative Bacteria

(2010) Karen Bush et al.   Annual Review of Microbiology

Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam  -Lactamase Inhibitor

(2010) T. Stachyra et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-ProducingKlebsiella pneumoniae

(2010) Andrea Endimiani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Alarming β-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae

(2010) Karen Bush   CURRENT OPINION IN MICROBIOLOGY

In Vitro Activity of NXL104 in Combination with  -Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases

(2009) A. Endimiani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of the  -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

(2009) T. Stachyra et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum  -lactamases and carbapenemases

(2008) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY